<DOC>
	<DOCNO>NCT01183949</DOCNO>
	<brief_summary>The purpose study determine whether AT7519M alone AT7519M plus bortezomib effective treatment patient previously treat multiple myeloma .</brief_summary>
	<brief_title>Effect AT7519M Alone AT7519M Plus Bortezomib Patients With Previously Treated Multiple Myeloma</brief_title>
	<detailed_description>The clinical study AT7519M/0004 open-label multicenter study investigate efficacy AT7519M alone AT7519M combination bortezomib patient previously treat multiple myeloma ( MM ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Ability understand risk study provide sign informed consent Age 18 year old Relapsed Refractory MM Disease progression follow least two systemic treatment MM Patient must refractory last bortezomib ECOG performance status 0 , 1 2 Pregnant lactating female . Patients childbearing potential must use appropriate birth control throughout study Inadequate liver function Renal impairment Neutrophil count &lt; 1.0 x 10^9 /litre absence growth factor Platelet count &lt; 50 x 10^9 /litre patient &lt; 50 % bone marrow nucleate cell plasma cell &lt; 30 x 10^9 /litre patient ≥50 % bone marrow nucleate cell plasma cell Hemoglobin &lt; 8g/dl absence transfusion Treated correct calcium &gt; ULN Serum creatine phosphokinase &gt; ULN All previous cytotoxic therapy MM must complete least four week prior treatment AT7519M ( two week noncytotoxic therapy ) Patients may receive concomitant therapy biphosphonates low dose corticosteroid . Bisphosphonates dose stable least 30 day prior study drug administration . Corticosteroids dose stable least 7 day prior study treatment Prior peripheral stem cell transplant within 12 week Evidence mucosal internal bleeding and/or platelet transfusion refractory ( unable maintain platelet count &gt; 50 x 10^9 /litre ) Ongoing infection require treatment Previous radiotherapy within 2 week start study Having previously receive treatment cyclindependent kinase GSK3beta inhibitor Incomplete recovery previous radiotherapy residual cutaneous effect stable &lt; Grade 2 gastrointestinal toxicity Prior radiotherapy head neck region head neck tumor Previous malignancy , except nonmelanomatous skin carcinoma , situ carcinoma malignancy low risk recurrence . Any severe uncontrolled systemic condition ( e.g . systemic infection ) current unstable uncompensated respiratory cardiac condition make undesirable patient participate study could jeopardize compliance protocol Incomplete recovery surgery stable &lt; Grade 2 toxicity Peripheral neuropathy &gt; Grade 2 Abnormal leave ventricular ejection fraction ( &lt; low limit normal institution patient age ) echocardiogram History ischemic cardiac event , include myocardial infarction within 3 month study entry Congestive cardiac failure ≥ grade 3 severity accord NYHA functional classification Unstable cardiac disease History presence bradycardia ( ≤60bpm ) , leave bundle branch block , heart block , cardiac pacemaker significant atrial tachyarrhythmias If patient receive bortezomib ( Velcade ) part C study , concurrent treatment medication know strongly inhibit induce CYP3A4 , CYP1A2 CYP2C19 discontinue least two week prior treatment AT7519M ( corticosteroid ) Concurrent treatment medication prolongs QT interval may induce Torsades de Pointes discontinue least two week prior treatment AT7519M Family personal history long QTc syndrome ventricular arrhythmia include ventricular bigeminy Previous history druginduced QTc prolongation Screening 12lead ECG measurable QTc interval accord Fridericia 's Correction &gt; 450 msec Screening 12lead ECG ST depression &gt; 1 mm 2 lead T wave inversion 2 contiguous lead Prior history infection human immunodeficiency virus ( HIV ) , know active hepatitis B C viruses Diffuse infiltrative pulmonary pericardial disease Known hypersensitivity bortezomib , boron excipients VelcadeTM Epilepsy convulsive disorder require active management Serious psychiatric illness , active alcoholism drug addiction may hinder confuse follow evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms , Plasma Cell</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Hemostatic Disorders</keyword>
	<keyword>Paraproteinemias</keyword>
	<keyword>Blood Protein Disorders</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Hemorrhagic Disorders</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Antineoplastic Agents</keyword>
</DOC>